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Abstract. Global Program to Eliminate Lymphatic Filariasis (GPELF) guidelines call for using filarial antigen testing
to identify endemic areas that require mass drug administration (MDA) and for post-MDA surveillance. We compared a
new filarial antigen test (the Alere Filariasis Test Strip) with the reference BinaxNOW Filariasis card test that has been
used by the GPELF for more than 10 years. Laboratory testing of 227 archived serum or plasma samples showed that the
two tests had similar high rates of sensitivity and specificity and > 99% agreement. However, the test strip detected
26.5% more people with filarial antigenemia (124/503 versus 98/503) and had better test result stability than the card test
in a field study conducted in a filariasis-endemic area in Liberia. Based on its increased sensitivity and other practical
advantages, we believe that the test strip represents a major step forward that will be welcomed by the GPELF and the
filariasis research community.
INTRODUCTION
Lymphatic filariasis (LF) is a deforming and disabling
neglected tropical disease (NTD) that has been targeted for
elimination by the year 2020.1 The Global Program to Elimi-
nate Lymphatic Filariasis (GPELF) aims to interrupt trans-
mission of the nematode worms that cause LF using periodic,
repeated mass drug administration (MDA) of antifilarial
medications to entire at-risk populations. Four billion doses
of these drugs were distributed in more than 50 disease-
endemic countries between the years 2000 and 2011,1,2 which
makes the GPELF the largest public health intervention pro-
gram to date based on MDA. TheWorld Health Organization
(WHO) has provided guidelines and protocols for mapping,
monitoring, and evaluating LF programs with diagnostic tests
that include detection of microfilariae (Mf) by microscopic
examination of stained blood smears and detection of circu-
lating filarial antigen (CFA) in human blood.3 CFA tests
detect a 200 kDa parasite antigen that is a sensitive and spe-
cific biomarker for the presence of adult Wuchereria
bancrofti, the parasite species that is responsible for 90% of
the LF disease burden in the world.4 CFA testing is much
more sensitive than thick smear microscopy for detecting W.
bancrofti infections, and it is also more convenient, because it
can be performed with blood collected during the day or night
in the field with no requirement for electricity, special equip-
ment, or skilled microscopists.5
The first sensitive CFA tests used monoclonal antibodies
in antigen-capture assays such as radioimmunoassay and
microplate enzyme-linked immunosorbent assay (ELISA).6–8
However, the development of a commercial, point-of-care
(POC) immunochromatographic (ICT) test in the late 1990s
allowed CFA testing to escape the confines of the research
laboratory and assume an important role as a tool for public
health use. Initially developed as the ICT Filariasis card test
in 1996 by ICT Diagnostics in Australia, the test has been
produced as the BinaxNOW Filariasis test in the United
States by Alere Scarborough (Scarborough, ME; formerly
Binax, Inc.) since 2000. Although it took some time for this
test to gain acceptance by the LF research and control com-
munities, it is now integrated into the GPELF protocols for
mapping LF endemicity, stopping MDA, and post-MDA sur-
veillance.9,10 Although this test is a valuable tool, its short
shelf life (3 months at ambient temperatures in the tropics)
and cost have hampered its use by the GPELF. Another
problem with the test is that it has a narrow time window for
reading the test result. The manufacturer’s instructions call
for reading the test 10 minutes after one closes the card to
start the test. False-positive results are common if the tests
are read too late (after 20 minutes).11
Recognizing the importance of affordable and reliable
diagnostic testing for the GPELF, the Bill and Melinda Gates
Foundation canvassed filariasis experts to outline a target
product profile for an improved CFA test and provided a
grant to the manufacturer for test development. This paper
reports results of an independent evaluation of the fruit of
that effort, the Alere Filariasis Test Strip. POC technologies
have improved in the past 15 years, and our results show that
the new test has significant advantages over its predecessor;
it will be marketed in 2013.
MATERIAL ANDMETHODS
Test materials and protocol. Test materials were provided at
no cost by Alere Scarborough, Inc. Test protocols were devel-
oped by the authors together with personnel at Alere Scarborough,
Inc. to comply with rigorous industry standards required for
Conformite Europeene (CE) marking and test registration.
Test performance, interpretation of test results, data analysis,
and manuscript preparation were conducted independently by
the authors.
Ethical approval. Laboratory evaluations with existing
serum or plasma samples were conducted under human stud-
ies protocols approved by institutional review boards (IRBs)
at the Centers for Disease Control (CDC) and Washington
University. The field study in Liberia was approved by IRBs
at Washington University and the University of Liberia in
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Monrovia. All adult participants in the field study provided
informed consent; assent by the child and consent from at least
one parent were required for children to participate in the study.
Laboratory evaluation of the two filarial antigen tests. This
evaluation was performed in two laboratories with well-
characterized panels of serum or plasma. The Washington Uni-
versity laboratory tested a panel of previously frozen serum or
plasma samples from human subjects with parasitologically
proven helminthic infections and control samples collected in
St. Louis, Missouri, which is non-endemic for human filariasis
and other human helminthic infections. The CDC laboratory
tested samples from Haiti that were collected in separate areas
of the country that were highly endemic and non-endemic for
LF. In both settings, venous blood samples were collected at
night from consenting subjects, and Mf status was assessed by
nuclepore filtration (1 mL). Mf counts for positive Haitian sam-
ples ranged from 1 to 3,144/mL. Additional non-endemic sam-
ples tested at the CDC were collected from US residents and
residents of an Argentinean community with a high prevalence
of soil-transmitted helminth infections and strongyloidiasis.12
Testing with the BinaxNOW Filariasis card test and the
Alere Filariasis Test Strip was performed according to the
manufacturer’s instructions. For the card test, 100 mL serum or
plasma were placed on the sample application pad, the card
was closed, and the test result was assessed at 10 minutes. For
the test strip, 75 mL serum or plasma were placed on the sample
application pad, and the test result was read by two indepen-
dent readers at 10 minutes. For the Washington University
evaluation, if the two readers’ results did not agree, a final
decision regarding the test result was made by a third reader.
Cards and test strips were also read by two readers 24 hours
after adding samples to the tests. Serum and plasma samples
were coded, and test readers read the samples blindly without
knowing the type of sample being tested or the result obtained
by the other reader. Analytical sensitivity of the two antigen
tests was compared by parallel testing of serial dilutions of a
filarial antigen (DATH; prepared as previously described).13
Field evaluation of the filarial antigen tests. The field
study was performed in Lofa County in northwestern Liberia.
The study villages were endemic for lymphatic filariasis,
onchocerciasis, schistosomiasis, and soil-transmitted helminth
infections. A single round of community-directed ivermectin
(MDA) had been distributed for onchocerciasis control in the
study area in November of 2011, approximately 5 months
before this study. Capillary blood was collected during the
day by finger prick with a disposable contact-activated lancet
(Becton Dickinson, Franklin Lakes, NJ). The blood was col-
lected directly into a small 75-mL blood collection pipette for
the Alere Filariasis Test Strip and a 100-mL capillary tube
supplied with the BinaxNOW Filariasis card test. All testing
was performed in the study villages immediately after blood
was collected. For the card test, 100 mL blood were placed on
the sample application pad, the card was closed, and the test
result was assessed at 10 minutes. For the test strip, 75 mL
blood were added to the sample application pad, and the test
result was assessed at 10 minutes. Both types of test were
independently read and scored by two readers. If the two
readers’ results did not agree, a final decision regarding the
test result was made by a third reader. Cards and test strips
were also read at 30 minutes and approximately 24 hours
after adding blood to the tests. Test scores were recorded as
follows: 0 = no test line visible (a negative test); 1+, the test
line is present but weaker than the control line; 2+, the test
line is equal to the control line; 3+, the test line is stronger
than the control line. Tests with no control line were consid-
ered to have invalid results. A majority of subjects enrolled in
the study was also tested for Mf by microscopic examination
of stained thick blood films (60 mL) prepared with finger-
prick blood collected between 9 PM and 12 AM.
RESULTS
Laboratory evaluation. The analytical sensitivity of the
two tests was compared by testing serial dilutions of DATH
filarial antigen with a starting concentration of 4 ng/mL. The
test strip produced stronger, sharper positive test lines than the
card, and the test strip was more sensitive than the card test
(Figure 1). The card test was weakly positive with antigen
diluted 1:4, and higher dilutions were cleanly negative. The test
strip was clearly positive with antigen diluted at 1:8, and a weak
shadow line was observed with antigen at 1:16. Thus, the mini-
mum concentration of antigen detected with the test strip was
two to four times lower than the minimum detected with the
card test.
Table 1
Laboratory comparison of the BinaxNOW Filariasis card test and the Alere Filariasis Test Strip using banked serum/plasma samples
Serum group Origin of samples No. tested
No. of positive tests
RemarksCard Strip
W. bancrofti Sri Lanka* 29 28 29 One card had an invalid result
W. bancrofti Haiti† 59 59 59 One card had an invalid result
Brugia timori Indonesia* 10 1 2 Sera were collected in an area that was coendemic
forW. bancrofti
Onchocerca volvulus Cameroon* 14 0 0 Five individuals were coinfected with L. loa
Mansonella perstans Uganda* 10 0 0 Two card tests had invalid results
Strongyloides stercoralis or hookworm Uganda* 10 0 1 Sera were collected in an area that was coendemic
forW. bancrofti
Non-endemic Haiti† 20 0 0
Non-endemic Argentina† 20 0 0
Non-endemic United States* 20 0 0 One test strip had an invalid result
Non-endemic United States† 25 0 0 One test strip had an invalid result
Non-endemic, RF ³ 1:64 United States* 10 0 0 RF > 1:64
Total 227 88 91
RF = rheumatoid factor.
*Samples tested at Washington University.
†Samples tested at The Centers for Disease Control and Prevention.
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Test results obtained with various types of infection and
control sera are summarized in Table 1. The two tests produced
the same results for 220 of 222 samples that had valid results for
both tests (99.1% agreement). Apart from one invalid card
test, both tests detected filarial antigenemia in all 88 samples
from subjects with W. bancrofti microfilaremia. Turning to
specificity results, 1 of 10 samples from Indonesian subjects
with brugian filariasis was positive by both tests, 1 was positive
by the test strip only, and 1 of 10 samples from Ugandan sub-
jects with strongyloidiasis was positive by the test strip only.
The positive brugian filariasis serum samples (from Alor
Island) and the positive strongyloidiasis serum sample were
from subjects who had lived in areas that were coendemic for
bancroftian filariasis.14 No positive results were observed with
either test for samples from subjects with no history of expo-
sure to bancroftian filariasis, regardless of whether they had
other parasitic infections or rheumatoid factor.
Card tests and test strips were reevaluated at 24 hours to
assess the stability of test results. In the Washington Uni-
versity laboratory, 7 of 71 card tests that were negative at
10 minutes were scored positive at 24 hours by both readers.
Two of these samples were samples that were positive by the
test strip at 10 minutes; one of these samples was from a
subject with strongyloidiasis, and the other was from a subject
with brugian filariasis. An additional 17 card tests that were
negative at 10 minutes had very faint shadow T lines at 24 hours
that were scored borderline positive by one of two readers;
1 of 71 test strips that were negative at 10 minutes was scored
positive at 24 hours by both readers. This test strip was a
non-endemic serum sample from the United States. Six
other test strips that were negative at 10 minutes had weak
shadow T lines that were scored borderline positive by one
of two readers at 24 hours.
The CDC laboratory also reported that some tests that
were negative at 10 minutes were positive at 24 hours,
although some of these tests were only judged to be positive
at the later time point by one reader; 5 of 65 test strips and
6 of 65 card tests that were negative at 10 minutes were
judged to be positive at 24 hours by at least one reader. All
of these late positive tests occurred with samples from
subjects with no history of exposure to filariasis.
Field evaluation. Sixteen test strips (3%) and one card test
(0.2%) had invalid results with no control line. Most of the
invalid test strip results occurred because the volume of blood
tested was less than 75 mL or blood was partially clotted
before testing. Most invalid test results occurred during the
first few days of using the test, and this problem became rare
as technicians gained experience using the plastic micropi-
pettes supplied with the test. It is important to avoid bubbles
and hold the micropipettes slightly above the horizontal plane
during blood collection. The single invalid card test result
occurred when too little blood was tested.
Whole-blood antigen test results are summarized in Table 2.
Study participants ranged in age from 6 to 89 years, and
approximately one-half of the subjects tested were female.
The sensitivity of the tests was compared for 503 blood sam-
ples that had valid results for both tests. The test strip pro-
duced 26 (26.5%) more positive test results than the card test
(124/503 versus 98/503). All but one of the samples with pos-
itive card tests were also positive by the test strip. Positive test
lines were sharper and easier to read in the test strip than the
card test. Night blood testing for Mf was performed for 109 of
124 subjects with positive filarial antigen tests. Only eight
subjects had Mf by thick smear (range = 1–51 Mf per 60 mL).
Seven samples from these subjects were positive for filarial
antigenemia by both tests; the other sample was positive by
the card test but had an invalid test strip result. No Mf were
detected in any of 344 night blood smears examined from
subjects with negative filarial antigen tests (Table 3).
For 97 blood samples that were positive by both antigen tests,
test strip scores were approximately one point higher than card
test scores (2.52, SD = 0.70 versus 1.58, SD = 0.68; P < 0.001,
Wilcoxon signed ranks test). Only 12 of 36 samples that pro-
duced weak (1+) positive test lines in the test strip had positive
card test results. However, 85 of 88 samples that produced
strong (2 + or 3+) test lines in the test strip had positive card
test results. This difference in agreement rates between the two
tests was statistically significant (P < 0.001 by c2) (Table 4).
Turning to the issue of test result stability, 4 of 379 (1.1%)
test strips that were negative at 10 minutes were positive at
30 minutes, and 36 (9.5%) were positive at 24 hours; 3 of 417
(0.7%) card tests that were negative at 10 minutes were posi-
tive at 30 minutes, and 264 (63.3%) were positive at 24 hours.
These results show that, although the test strip has better test
result stability than the card test, late positive tests were
Table 2
Test results by village from the field study in northwestern Liberia that compared the performance of the BinaxNOW Filariasis card test and the
Alere Filariasis Test Strip
Village No. tested Mean age (years; range) Female (%)
No. (%) of positive tests* No. (%) of invalid tests
Card test Test strip Card test Test strip
Sasanin† 102 29 (6–89) 54.9 11 (10.9) 16 (16.8) 1 (1.0)‡ 7 (6.7)
Felaloe 71 28 (6–80) 39.4 9 (12.7) 14 (20.0) 0 1 (1.4)
Sakawo 143 25 (6–70) 49.7 27 (18.9) 34 (24.5) 0 4 (2.8)
Kilima Bendu 97 26 (6–75) 47.4 26 (26.8) 27 (28.4) 0 2 (2.1)
Medikorma 106 38 (6–80) 55.7 27 (25.5) 33 (31.7) 0 2 (1.9)
Total 519 29 (6–80) 50.1 100 (19.3) 124 (24.7) 1 (0.2)‡ 16 (3.1)
*Percent shown only considers tests with valid results.
†The first village examined.
‡Both tests were invalid for this sample.
Table 3
Comparison of results obtained with the BinaxNOW Filariasis card
test and the Alere Filariasis Test Strip with blood samples collected
in Liberia
Card test result
Test strip result
Positive Negative Positive (%)
Positive (N = 98) 97 1 99.0
Negative (N = 405) 27 378 6.0
Total (% positive) 124 (78.2%) 379 (0.3%) –
Results presented are for 503 blood samples, with valid results for both tests.
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observed with both tests at 24 hours, and both tests should
be read at 10 minutes as instructed in the package inserts.
DISCUSSION
The BinaxNOW Filariasis card test is widely used in the
GPELF as an epidemiological tool for mapping filariasis
endemicity and assessing the success of LF elimination pro-
grams after MDA. It is also useful for detecting active filarial
infections in individual patients suspected of having LF. The
Alere Filariasis Test Strip is a next generation filarial antigen
test that was developed to improve on the card test. This study
was performed to validate the new test and compare its
performance with the performance of the card test.
Laboratory studies showed that the test strip has better
analytical sensitivity than the card test for detecting filarial
parasite antigen. However, the sensitivity and specificity of
the two tests were comparable in studies performed in two
laboratories with banked serum or plasma samples from indi-
viduals with W. bancrofti microfilaremia and various types of
control samples. Both tests detected antigenemia in all sam-
ples from subjects with microfilaremicW. bancrofti infections,
and neither test detected antigenemia in sera from people
with no history of exposure to bancroftian filariasis. The high
specificity of the new test was not surprising, because it is
based on the same reagents that are used in the card test,
which has high specificity. No single study can guarantee that
a new test will perform well in all settings; additional testing
with serum and whole-blood samples should be performed to
verify the apparent high specificity of the test strip.
The superior sensitivity of the test strip was more evident in
the field study than in the laboratory evaluation, because the
positive laboratory samples were all from Mf carriers, who
tend to have higher levels of antigenemia than people with
amicrofilaremic infections. The test strip generated 26.5%
more positive results in the field study than the card test.
Differences in antigen detection results between the two tests
may be even greater in areas where residual antigen levels are
low after multiple rounds of MDA. Additional studies should
be performed in such areas to test this hypothesis. The higher
sensitivity of the new test may significantly raise the bar for
LF elimination programs that use antigen test results to guide
decisions on when to stopMDAand for post-MDA surveillance
activities such as transmission assessment surveys (TAS).10
Both antigen tests detected CFA in all samples from
W. bancrofti Mf carriers tested in the laboratory and field
studies. However, relatively few of the antigen-positive sub-
jects in the field study had Mf detected by night blood thick
smears. This result probably reflects the impact of ivermectin
MDA that study communities received a few months before
the field study. Pilot surveys performed in the study area less
than 1 year before our study (and before ivermectin) found
that 46% of those individuals with positive card tests for filar-
ial antigenemia had Mf detected in 60 mL night blood thick
smears. This percentage is consistent with results reported
from other areas that were studied before MDA.15,16 The
small number of Mf carriers in the field study does not detract
from the results; the card test and test strip detect an adult
filarial worm antigen in human blood, and they are not
designed to detect Mf.
Other than improved sensitivity, other advantages of the
test strip relative to the card test are that it is expected to
have a longer shelf life at ambient temperatures (15–37°C)
and significantly lower purchase and shipping costs for the
GPELF. These factors should further improve the field
applicability of antigen testing for resource-challenged LF
elimination programs. Although the test strip requires slightly
less blood than the card test, some practice was required to
properly use the micropipettes supplied with the test strips.
Users should carefully follow the manufacturer’s instructions
for the new test.
Our results show that the new test has not completely
solved the problem of test result stability. Preliminary obser-
vations suggest that this problem can be solved by removing
the sample application pad from the test strip with a scissors
at the 10-minute time point and placing a drop of isopropyl
alcohol on the nitrocellulose membrane. Readers should
understand that this off-label modification of the test protocol
has not been evaluated or validated by the manufacturer.
However, the authors believe that it may be useful when tests
are performed in field situations with poor lighting conditions
that prevent accurate reading of test results at 10 minutes.
In summary, our results show that the new Alere Filariasis
Test Strip has significant technical and practical advantages
over the BinaxNOW Filariasis card test. Although additional
Figure 1. Left shows a strongly positive Alere Filariasis Test Strip
(the lower line is the T or test line; score of 2+). Right shows a weakly
positive BinaxNOW Filariasis card test (score of 1+). The tests were
performed with the same blood sample, and the photograph was
taken 10 minutes after starting the tests.
Table 4
Comparison of test scores obtained during the field study with the
BinaxNOW Filariasis card test and the Alere Filariasis Test Strip
for samples that were positive by either test
Test strip score
Card test score
Total0 1 2 3
0 0 1 0 0 1
1 25 11 0 0 36
2 2 20 4 0 26
3 1 19 32 10 62
Total 28 51 36 10 125
These results were obtained with human blood samples (10-minute time point).
14 WEIL AND OTHERS
studies are needed to compare the performance of these
two CFA tests in areas with low residual LF endemicity rates
after multiple rounds of MDA, we believe that the new test
represents a major step forward that will be welcomed by the
GPELF and the filariasis research community.
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